Vyant Bio (NASDAQ:VYNT – Get Rating) had its target price lowered by equities research analysts at HC Wainwright to $3.00 in a research note issued to investors on Tuesday, Stock Target Advisor reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 338.34% from the company’s current price.
Separately, Zacks Investment Research downgraded shares of Vyant Bio from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th.
Shares of NASDAQ VYNT traded up $0.00 during trading hours on Tuesday, hitting $0.68. 500 shares of the company’s stock were exchanged, compared to its average volume of 51,028. The company’s 50-day moving average price is $1.08 and its 200-day moving average price is $1.38. Vyant Bio has a 1-year low of $0.64 and a 1-year high of $4.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.27 and a quick ratio of 4.19.
Vyant Bio Company Profile (Get Rating)
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
- Get a free copy of the StockNews.com research report on Vyant Bio (VYNT)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
- Time to Ride These 3 Mid Cap Momentum Plays
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.